Correct. In absence of a need to raise additional capital - the current drop in shareprice does not actually hurt the ability of the company in moving forward in TOX or Clinical testing.
It is painful for current shareholders who were looking for a quick ROI. I know I don't like looking at the balance on my accounts due to NNVC at present.
But, I am not needing a quick ROI - so I can wait for the company to get the work done.
Those who can't wait it out - have had to make their own tough choices.
And that money in the bank is supposed to be segregated right ? Well, it won't be once it goes thru the lab. It will come out 'sterilized', and up-in-smoke as expenses. Perhaps management will then offer a PIPE.
Investors in this sled will lose everything. If not convinced yet, then go ALL IN, and then later you will be.
NNVC has plenty of money in the bank, so the lower share price won't affect progress toward Phase I trials.